Centre Hospitalier de Luxembourg

0

BACKGROUND: Unconscious survivors of out-of-hospital cardiac arrest have a high risk of death or poor neurologic function. Therapeutic hypothermia is recommended by international guidelines, but the supporting evidence is limited, and the target temperature associated with the best outcome is unknown. Our objective was to compare two target temperatures, both intended to prevent fever. METHODS: In an international trial, we randomly assigned 950 unconscious adults after out-of-hospital cardiac arrest of presumed cardiac cause to targeted temperature management at either 33°C or 36°C. The primary outcome was all-cause mortality through the end of the trial. Secondary outcomes included a composite of poor neurologic function or death at 180 days, as evaluated with the Cerebral Performance Category (CPC) scale and the modified Rankin scale. RESULTS: In total, 939 patients were included in the primary analysis. At the end of the trial, 50% of the patients in the 33°C group (235 of 473 patients) had died, as compared with 48% of the patients in the 36°C group (225 of 466 patients) (hazard ratio with a temperature of 33°C, 1.06; 95% confidence interval [CI], 0.89 to 1.28; P=0.51). At the 180-day follow-up, 54% of the patients in the 33°C group had died or had poor neurologic function according to the CPC, as compared with 52% of patients in the 36°C group (risk ratio, 1.02; 95% CI, 0.88 to 1.16; P=0.78). In the analysis using the modified Rankin scale, the comparable rate was 52% in both groups (risk ratio, 1.01; 95% CI, 0.89 to 1.14; P=0.87). The results of analyses adjusted for known prognostic factors were similar. CONCLUSIONS: In unconscious survivors of out-of-hospital cardiac arrest of presumed cardiac cause, hypothermia at a targeted temperature of 33°C did not confer a benefit as compared with a targeted temperature of 36°C. (Funded by the Swedish Heart-Lung Foundation and others; TTM ClinicalTrials.gov number, NCT01020916.).

OBJECTIVE: To describe the development of the World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0) for measuring functioning and disability in accordance with the International Classification of Functioning, Disability and Health. WHODAS 2.0 is a standard metric for ensuring scientific comparability across different populations. METHODS: A series of studies was carried out globally. Over 65,000 respondents drawn from the general population and from specific patient populations were interviewed by trained interviewers who applied the WHODAS 2.0 (with 36 items in its full version and 12 items in a shortened version). FINDINGS: The WHODAS 2.0 was found to have high internal consistency (Cronbach's alpha, α: 0.86), a stable factor structure; high test-retest reliability (intraclass correlation coefficient: 0.98); good concurrent validity in patient classification when compared with other recognized disability measurement instruments; conformity to Rasch scaling properties across populations, and good responsiveness (i.e. sensitivity to change). Effect sizes ranged from 0.44 to 1.38 for different health interventions targeting various health conditions. CONCLUSION: The WHODAS 2.0 meets the need for a robust instrument that can be easily administered to measure the impact of health conditions, monitor the effectiveness of interventions and estimate the burden of both mental and physical disorders across different populations.

Romain Meeusen, Belgium (Chair) Martine Duclos, France Carl Foster, United States Andrew Fry, United States Michael Gleeson, United Kingdom David Nieman, United States John Raglin, United States Gerard Rietjens, the Netherlands Jürgen Steinacker, Germany Axel Urhausen, Luxembourg ABSTRACT Successful training not only must involve overload but also must avoid the combination of excessive overload plus inadequate recovery. Athletes can experience short-term performance decrement without severe psychological or lasting other negative symptoms. This functional overreaching will eventually lead to an improvement in performance after recovery. When athletes do not sufficiently respect the balance between training and recovery, nonfunctional overreaching (NFOR) can occur. The distinction between NFOR and overtraining syndrome (OTS) is very difficult and will depend on the clinical outcome and exclusion diagnosis. The athlete will often show the same clinical, hormonal, and other signs and symptoms. A keyword in the recognition of OTS might be “prolonged maladaptation” not only of the athlete but also of several biological, neurochemical, and hormonal regulation mechanisms. It is generally thought that symptoms of OTS, such as fatigue, performance decline, and mood disturbances, are more severe than those of NFOR. However, there is no scientific evidence to either confirm or refute this suggestion. One approach to understanding the etiology of OTS involves the exclusion of organic diseases or infections and factors such as dietary caloric restriction (negative energy balance) and insufficient carbohydrate and/or protein intake, iron deficiency, magnesium deficiency, allergies, and others together with identification of initiating events or triggers. In this article, we provide the recent status of possible markers for the detection of OTS. Currently, several markers (hormones, performance tests, psychological tests, and biochemical and immune markers) are used, but none of them meet all the criteria to make their use generally accepted. Key Words: OVERTRAINING SYNDROME, OVERREACHING, TRAINING, PERFORMANCE, UNDERPERFORMANCE The goal in training competitive athletes is to provide training loads that are effective in improving performance. During this process, athletes may go through several stages within a competitive season of periodized training. These phases of training range from insufficient training, during the period between competitive seasons or during active rest and taper, to “overreaching” (OR) and “overtraining” (OT), which includes maladaptations and diminished competitive performance. Literature on “OT” has increased enormously; however, the major difficulty is the lack of common and consistent terminology as well as a gold standard for the diagnosis of OT syndrome (OTS). In 2006, the European College of Sport Science (ECSS) published its consensus statement on OT (94). We decided to write an update and to ask the American College of Sports Medicine to provide input in this article so that this can be considered as a mutual “consensus statement” of both international organizations. In this “consensus statement,” we will present the current state of knowledge on the OTS going through its definition, diagnosis, treatment, and prevention. DEFINITION Successful training must involve overload but also must avoid the combination of excessive overload with inadequate recovery. The process of intensifying training is commonly used by athletes in an attempt to enhance performance. As a consequence, the athlete may experience acute feelings of fatigue and decreases in performance as a result of a single intense training session or an intense training period. The resultant acute fatigue after an adequate rest period can be followed by a positive adaptation or improvement in performance and is the basis of effective training programs. However, if the balance between appropriate training stress and adequate recovery is disrupted, an abnormal training may and a state of may the evidence for a after of training is not recent to the of for the of OT and of training and/or stress in short-term decrement in performance with or without and psychological signs and symptoms of in which of performance may from several to several of training and/or stress in decrement in performance with or without and psychological signs and symptoms of in which of performance may several or As by several that the between OT and is the of for performance and not the or of training stress or of These also that there may be an of psychological signs with the is possible to from a state of within a period may be that this is a and of the training However, athletes are in an state may or to The difficulty in the that might between athletes and those an The also that show and that the OT may be an avoid of we the and OTS on the used by and and and In “OT” is used as a a process of training with possible of short-term or OTS. the we the etiology and that is not the of the is often used by athletes during a training to enhance performance. training can result in a in however, appropriate of recovery are a may with the athlete an performance with This process is often used going on a and will lead to a performance which is followed by performance. In this the will the stress This of short-term can also be When this the athletes can a state of or which will lead to a or in performance that will not for several or However, athletes will be to after that not only the on the is by the in training but also signs and symptoms of psychological and/or This is in with the of and recent a In the stages that training from and and from OTS are can be as a process of overload that is used to which in acute fatigue to an improvement in performance. When training or athletes use a short-term period training to training can experience short-term performance decrement without severe psychological or lasting other negative symptoms. This short-term will eventually lead to an improvement in performance after recovery. However, athletes do not sufficiently respect the balance between training and recovery, NFOR can occur. this the signs and symptoms of training such as performance psychological increased and hormonal will and the athletes will or to factors such as inadequate and/or carbohydrate infections and and may be this the distinction between NFOR and OTS is very difficult and will depend on the clinical outcome and exclusion diagnosis. The athlete will often show the same clinical, hormonal, and other signs and symptoms. the diagnosis of OTS can often only be the can be A keyword in the recognition of OTS might be “prolonged maladaptation” not only of the athlete but also of several biological, neurochemical, and hormonal regulation of the stages of training, and between performance and performance to is This to and biochemical The OTS is by the that the clinical are from to and are and in recent the knowledge of of OTS has there is a for for the diagnosis of OTS. OTS is by a in performance together with in mood This a period of recovery lasting several or there is no to an athlete as OTS, the to the diagnosis can only be by all other possible on in performance and mood if no for the can be OTS is and recognition of OTS is the only is a in performance during or training. The diagnosis of OTS the exclusion of an organic or and iron with or diseases and major or such as and also be However, be that and clinical to and OTS can other The between and is very difficult to In is generally thought that symptoms of OTS, such as fatigue, performance decline, and mood disturbances, are more severe than those of However, there is no scientific evidence to either confirm or refute this suggestion. there is no evidence that the athlete is OTS. In in the that a state of of the and biochemical to the increased training with in and others and the of and OTS and not This is also the signs and symptoms of OTS are and is not and to an athlete in such a that will OTS. are and only on OTS. One approach to understanding the etiology of OTS involves the exclusion of organic diseases or infections and factors such as dietary caloric restriction (negative energy balance) and insufficient carbohydrate and/or protein intake, iron deficiency, magnesium deficiency, allergies, and so on together with identification of initiating events or triggers. One of the is a training in an between and recovery. possible might be the of training, and and of commonly are and However, scientific evidence is not for of triggers. such as or infections may to or OTS but might not be present the the athlete to a possible initiating events has not the of the OTS. that the OTS be as the syndrome that on the of in OTS than on the mechanisms. This terminology has not the Athletes and the of in if a for the diagnosis of OTS. no this but there is a for a combination of to possible markers for OTS. there is a for a detection for training loads as well as other can the However, this is not which eventually to OTS. of and there are several possible recent on for the the OTS. more are a of athletes may the is or are It is difficult to on not all the of and other athletes a training a of of in other but are by of and OTS. The of the of an of of and of of OTS, with a of in of OTS by a from with OTS common and a in athletes can be to or but a recent of with the to These both the of OTS for athletes and the of in OTS there is evidence that athletes OTS are a of In a of that of the OTS during their training season with OTS in or more of the of training. In only of of OTS during their of a diagnosis of OTS This in the for has in athletes the same overload training. In a of competitive of training the same and the training but others the training and athletes of mood and of so by the training that to be from the It that are to the OTS to overload training or to the OTS the of of psychological factors and not the of OTS to be by or OT OTS the attempt of the to with and other that OTS the of such as training, to to and of and OTS can be within the of the of to this the is to the stress The and all to and enhance the of the to stress may lead to to on the as well as on the with the either to an or increased or and adaptation in will the that the state of or OTS the of the It has that acute stress not only but also and stress and the an in the of to acute has that in acute and the of The lack of criteria for OTS is in of the and “OT” by a lack of consistent are several criteria that a for the of the OTS must the be to the training and be by other factors and in the the of the OTS, and in to acute be from the be to with a of the not are not well and not the be rest from or of in not to with the training However, none of the or markers meet all of In training, to and are in and as well as the of and is this is of the of OTS, is athletes are is also not may can be on the training status of the factors that are in are the status and possible decreases in and to increased training. One consistent in and athletes the OTS, is a diminished or increased of which to and with lasting from several to to a and/or rest may provide an and/or but are not to an or OTS state with not only during of but also and after single to a with a to the the positive to training for several of with short-term of performance and mood well as a and a to after of training in well The of has as a possible of excessive training stress However, not all a during of increased training and OT and are not a of in OTS, other the as an of of the and are not of or OTS, are in on the status of the athlete and in the The with are as are within the of the and depend on the of the are in may with increased training but is not a consistent in OTS. several has that a hormonal during the of the OTS, and that of to the OTS The of the to this is from of factors that the of intake, after the of may the hormonal In and/or detection of the used may between of regulation functional that are considered and and are and the of is the of all are by the by other or This is the of is for the of hormonal also the that to regulation are by more than a single in a a the considered as an of the This decreases in to the and of training, and is that this only the of training and be used for diagnosis of or OTS of the that and OTS must be on a with a an and a of the and all other the adaptation to training is by increased only during recovery to to and by of to However, be that during a in of is and in are to those of an of the this is in with the in the of as in the of and are during and with and can be that is not a is no consensus or of for the of the training and/or an an a or no of a with training, or OTS. other than training and result in between factors and of and the between or and performance or training is is to use in as a to training In OTS, a in and in to a is the acute hormonal to the to the by the OTS is not that can be used for diagnosis is A of is by the and has to with in These on the and are in the hormonal regulation of and training However, the same to energy deficiency, which can be with training and/or of the training status or of energy the stress and to and might also be of the factors that can lead to the of OTS. In to the to hormonal in is also to the of hormonal the hormonal during the hormonal during recovery and is to both phases of this a that not only the to the recovery of the athlete but also can the to the of be to signs of OTS and them from training or published a with by The use of of to to an of and to a In the an in the of the after both the and the The be used as an of on the status of the hormonal after the will be This has the to a state of NFOR from the OTS. In an a to a of on the same is in an NFOR the hormonal to a a after the the same has that athletes OTS an in after the followed by a in the This a of the followed by an or that used a In a between and OTS athletes It that the use of is more in for detection of may be very in the of OTS. such as and as well as such as and as for the of training The that of in the state or may provide and may after training or inadequate recovery, there are no the possible of as markers of training stress or for the or diagnosis of or OTS. In the is of the major in the to acute stress and adaptation to A of is in such all in the to the of the However, the current the and that between athletes to and those to and symptoms of OTS. and/or will be for the of a hormonal for The with hormonal are as factors and factors to and/or of the stress of the and of and/or can either the of and or their in to and of the of which the to In the hormonal will depend on the of the and rest and after acute and of the to be with from the same and of used to by of the to to can be during the recovery of In athletes as OTS, several signs and symptoms with this between training and recovery. However, markers for between and athletes OTS are A of OTS is the to intense a performance the training is or increased Athletes OTS are to a training or a their training but are not to the training are or as The of OTS can be considered an in performance. an is considered to be for the diagnosis of OTS It that both the of performance used and the of the are in the in performance with OTS. as to which performance is the appropriate to and OTS. In will show in as a result of and OTS than more the of but only used to the performance in In that the of hormonal and can be a and performance might be to use performance of performance may be appropriate in and to be in but increased after of The with performance are as are often not and the of performance may not be are and of the be to of from to and from to performance are not do not to but tests, for of an are difficult to in In this adequate of is may be that training by are to the and of performance The of psychological symptoms in of OTS has but on this not in the on and athletes in other the a that both and athletes to in negative fatigue, and and decreases in the positive mood of during of training. that mood state a with training in a as training loads in or with the of training and mood training result in a in negative and an in such that the of a taper, the mood to the positive the of the the between training and mood state in more than athletes in a of and training also that mood of and athletes do not are to training also of disturbances, and of to increased training are and in the of When involve in training a of the to psychological if be to a more state of mood by to or that as as of training can result in in and on other psychological which in commonly used biochemical markers of training stress such as for the of athletes with signs of OTS both a in mood and a of mood with athletes the same training from symptoms fatigue and show the during overload training, and the of all in athletes signs of OTS, the of all with that to of athletes show signs of clinical As in mood between and of in mood from to overload training in OTS or of symptoms from and to of mood state as a to training with the goal of the of OTS. This the training of athletes mood within an range a either of athlete or the for the same training training loads increased in athletes only mood disturbances, and this as as in which training loads a of OTS with but and adequate generally the use of psychological for of OTS, several that can The is psychological those with of a or The common of involves or in which to present in a positive that can the of the with the or in the of OT to training an period can result in a of in which to in a The of can be by are in the of psychological athletes and their will and not be used for and by the of psychological there are no or to to the A the is the that the of the mood to training is not after in training in either or other are to often or during training this is to the stress of major a more the for use in and and that provide and for athletes in the of several psychological of and mood several for In the of OTS, the to use a or not only on published evidence of its and but also the of the is the of OTS is a of the of an athlete is training or a that or be if and are as or only to the OTS, to to the of training be and other OT in the attempt to enhance its and a on of from and A may be The and more in OT athletes with mood or and of the in several to be in OTS. a energy by fatigue from to during an training The athletes the after and in the to mood state after training and recovery. energy to both training stress and recovery, to the the be a to NFOR during intense but training OTS psychological and factors be with OTS. the has the for Athletes a factors that both OT and recovery in the current both of stress and recovery has the possible that may be symptoms of OT and fatigue, and are to However, stress and recovery are often in their with its by other the is to in training in athletes with signs of OTS OTS the of the Sport a that athletes mood and symptoms of OT during the in and the of in a with and the a In has for the of psychological in both and athletes overload training. however, a for of the and of and to that psychological with to enhance their A but in the detection of and a in an OTS is the of The of other in the that is to use in the by a The are to by the and It is well that symptoms such as and and are common in fatigue syndrome symptoms also in OTS These to the use of and for detection of and OTS. used a as a detection for a in in a of after their training a period of on the more difficult in the with the more to This outcome that is an in the between and In with a in in after a training In a in which OTS a of during a that fatigue is an the of This is by the of an after These that and are in detection of and OTS. However, more scientific are to which of are the for The with psychological are as state and other factors can be by to training and recovery. if on psychological use mood or of and training be more can be or by of or must be with the appropriate and on the training must be with state of mood can be by to be to the of psychological to and athletes may be or be in the and of the several as to which might be of or OTS. after increased training may be the result of of a to and of in or may be the result of a with other in might be a of a in and not to and be that of are not in athletes OTS has used as a of with an in an in to the of training on of but to in or OTS with either no or in increased the training of by a training to fatigue, and and all in to the however, all of there no in or the of to both in the and after no in and balance in athletes after of training. This the of balance by and In both the and in the during rest and in to that in the a to in to training in the as This may and/or increased However, in this increased and in a single athlete with In with during the same the an in and in the during training, which after recovery. The in to be the result of increased that the after to training with the of performance after in but to there are no published from athletes in or OTS. In a very recent in a of a of after and an of of with positive to training, but the not of markers not of a performance A that short-term overload training in an increased and a between and However, this no the after training lasting the only a the often in a clinical that such as or other in athletes be by a state of or OTS, this not by or OTS. However, be that an by the in an athlete in training may the to a of a and The with are as to be a in but not provide consistent One to be as an outcome there are to and the Currently, there is no consensus the and the of The present do not to between in from and OTS. are on to increased training, and also in and OTS It that training to or may both the of the and the of the resultant However, the of scientific to is are that of and has but on the immune to in and and in stress and and The immune and stress are with an of during the period after competitive and events These that immune and increased may result training is to and OTS, but to this that the of of training on immune and on to that several of to be to the training A period of training in with a in the In and and and of rest after of training in and to be after in the training in athletes a in A with training, and not a negative between and of with of training, several of both and are of or and to may to in athletes in immune during of training However, this often involves not only but also dietary energy deficiency, and psychological These are to a of that the that athletes to a training the of a to competitive a of of both and In commonly either the of the season or after the of training and/or athletes are not immune is possible that the of in several immune may to common such as immune with training may to of major However, might be that the increased the increased stress with increased training, of the of the athlete to the increased symptoms of by athletes may be to from than with a that immune is in athletes OTS is of insufficient scientific However, from athletes and of an increased with OTS by a In a of athletes the more than of the athletes symptoms of “OT” with with none of the athletes in the In during and after a training of the In a by competitive athletes with fatigue and performance a which with the to fatigue and/or infections in of the The common immune and of in of the athletes a to period has to mood state and that a of athletes are as OTS may experience increased are only a of in immune status in athletes with athletes and on athletes to of with and training. training, the However, this has not to be in athletes as OTS with One has that the of other on the of to be to between the of athletes and The of on not the of in athletes OTS with this “OT” be with and However, is a of and of on may be of the of acute which of a possible of the a in markers in of infections are not in but may be this in fatigue and in training and might be of the factors that can lead to the of OTS, or in the diagnosis of OTS be from a state of fatigue such as that with of In the OTS is to for and infections and diseases with the in OTS. It is in the in the of OTS, a of can be which may to the of symptoms. However, that this distinction between and may be in may in the and of fatigue and of OTS in When training the of in performance a for OTS. The with the in of other major diseases that are to are performance are and possible and diseases are This is on the evidence together with the of the is that the immune is to and immune be used as an of stress in to training. The current the immune and that of training result in immune with or no in However, immune in to increased training

The availability of allergen molecules ('components') from several protein families has advanced our understanding of immunoglobulin E (IgE)-mediated responses and enabled 'component-resolved diagnosis' (CRD). The European Academy of Allergy and Clinical Immunology (EAACI) Molecular Allergology User's Guide (MAUG) provides comprehensive information on important allergens and describes the diagnostic options using CRD. Part A of the EAACI MAUG introduces allergen molecules, families, composition of extracts, databases, and diagnostic IgE, skin, and basophil tests. Singleplex and multiplex IgE assays with components improve both sensitivity for low-abundance allergens and analytical specificity; IgE to individual allergens can yield information on clinical risks and distinguish cross-reactivity from true primary sensitization. Part B discusses the clinical and molecular aspects of IgE-mediated allergies to foods (including nuts, seeds, legumes, fruits, vegetables, cereal grains, milk, egg, meat, fish, and shellfish), inhalants (pollen, mold spores, mites, and animal dander), and Hymenoptera venom. Diagnostic algorithms and short case histories provide useful information for the clinical workup of allergic individuals targeted for CRD. Part C covers protein families containing ubiquitous, highly cross-reactive panallergens from plant (lipid transfer proteins, polcalcins, PR-10, profilins) and animal sources (lipocalins, parvalbumins, serum albumins, tropomyosins) and explains their diagnostic and clinical utility. Part D lists 100 important allergen molecules. In conclusion, IgE-mediated reactions and allergic diseases, including allergic rhinoconjunctivitis, asthma, food reactions, and insect sting reactions, are discussed from a novel molecular perspective. The EAACI MAUG documents the rapid progression of molecular allergology from basic research to its integration into clinical practice, a quantum leap in the management of allergic patients.

AIMS: The EURO-ENDO registry aimed to study the management and outcomes of patients with infective endocarditis (IE). METHODS AND RESULTS: Prospective cohort of 3116 adult patients (2470 from Europe, 646 from non-ESC countries), admitted to 156 hospitals in 40 countries between January 2016 and March 2018 with a diagnosis of IE based on ESC 2015 diagnostic criteria. Clinical, biological, microbiological, and imaging [echocardiography, computed tomography (CT) scan, 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT)] data were collected. Infective endocarditis was native (NVE) in 1764 (56.6%) patients, prosthetic (PVIE) in 939 (30.1%), and device-related (CDRIE) in 308 (9.9%). Infective endocarditis was community-acquired in 2046 (65.66%) patients. Microorganisms involved were staphylococci in 1085 (44.1%) patients, oral streptococci in 304 (12.3%), enterococci in 390 (15.8%), and Streptococcus gallolyticus in 162 (6.6%). 18F-fluorodeoxyglucose positron emission tomography/computed tomography was performed in 518 (16.6%) patients and presented with cardiac uptake (major criterion) in 222 (42.9%) patients, with a better sensitivity in PVIE (66.8%) than in NVE (28.0%) and CDRIE (16.3%). Embolic events occurred in 20.6% of patients, and were significantly associated with tricuspid or pulmonary IE, presence of a vegetation and Staphylococcus aureus IE. According to ESC guidelines, cardiac surgery was indicated in 2160 (69.3%) patients, but finally performed in only 1596 (73.9%) of them. In-hospital death occurred in 532 (17.1%) patients and was more frequent in PVIE. Independent predictors of mortality were Charlson index, creatinine > 2 mg/dL, congestive heart failure, vegetation length > 10 mm, cerebral complications, abscess, and failure to undertake surgery when indicated. CONCLUSION: Infective endocarditis is still a life-threatening disease with frequent lethal outcome despite profound changes in its clinical, microbiological, imaging, and therapeutic profiles.

Mitochondrial and lysosomal dysfunction have been implicated in substantia nigra dopaminergic neurodegeneration in Parkinson's disease (PD), but how these pathways are linked in human neurons remains unclear. Here we studied dopaminergic neurons derived from patients with idiopathic and familial PD. We identified a time-dependent pathological cascade beginning with mitochondrial oxidant stress leading to oxidized dopamine accumulation and ultimately resulting in reduced glucocerebrosidase enzymatic activity, lysosomal dysfunction, and α-synuclein accumulation. This toxic cascade was observed in human, but not in mouse, PD neurons at least in part because of species-specific differences in dopamine metabolism. Increasing dopamine synthesis or α-synuclein amounts in mouse midbrain neurons recapitulated pathological phenotypes observed in human neurons. Thus, dopamine oxidation represents an important link between mitochondrial and lysosomal dysfunction in PD pathogenesis.

BACKGROUND: Twenty-four-hour ambulatory blood pressure monitoring (ABPM) is an essential tool in the diagnosis and therapeutic monitoring of arterial hypertension in children. The statistical use of pediatric ABPM reference values has been compromised by the non-Gaussian distribution of 24-h blood pressure (BP) in children. OBJECTIVE: To develop distribution-adjusted pediatric ABPM reference tables. METHODS: From cross-sectional ABPM data obtained in 949 healthy children and adolescents aged 5-20 years, a set of reference tables was developed for 24-h, daytime and night-time mean values of systolic, diastolic, mean arterial BP and heart rate, utilizing the LMS method to account for the variably skewed distribution of ABPM data. Age- and gender-specific estimates of the distribution median (M), coefficient of variation (S) and degree of skewness (L) were obtained by a maximum-likelihood curve-fitting technique. The estimates of, and can be used to normalize ABPM data to gender and age or height. RESULTS: Re-application of the established, and values in the reference population confirmed appropriate normalization of ABPM values. Height standard deviation scores (SDS), body mass index (BMI) SDS and heart rate SDS were independent positive predictors of 24-h systolic BP SDS. Diastolic 24-h mean BP SDS showed a weak correlation with BMI SDS only. CONCLUSIONS: The use of LMS reference tables permits calculation of appropriate SDS values for ABPM in children. Whereas systolic 24-h BP is independently correlated with age, relative height and obesity, diastolic values are almost independent of age and relative height, and weakly associated with relative obesity.

BACKGROUND: Small RNA molecules, called microRNAs, freely circulate in human plasma and correlate with varying pathologies. In this study, we explored their diagnostic potential in a selection of prevalent cardiovascular disorders. METHODS AND RESULTS: MicroRNAs were isolated from plasmas from well-characterized patients with varying degrees of cardiac damage: (1) acute myocardial infarction, (2) viral myocarditis, (3) diastolic dysfunction, and (4) acute heart failure. Plasma levels of selected microRNAs, including heart-associated (miR-1, -133a, -208b, and -499), fibrosis-associated (miR-21 and miR-29b), and leukocyte-associated (miR-146, -155, and -223) candidates, were subsequently assessed using real-time polymerase chain reaction. Strikingly, in plasma from acute myocardial infarction patients, cardiac myocyte-associated miR-208b and -499 were highly elevated, 1600-fold (P<0.005) and 100-fold (P<0.0005), respectively, as compared with control subjects. Receiver operating characteristic curve analysis revealed an area under the curve of 0.94 (P<10(-10)) for miR-208b and 0.92 (P<10(-9)) for miR-499. Both microRNAs correlated with plasma troponin T, indicating release of microRNAs from injured cardiomyocytes. In viral myocarditis, we observed a milder but significant elevation of these microRNAs, 30-fold and 6-fold, respectively. Plasma levels of leukocyte-expressed microRNAs were not significantly increased in acute myocardial infarction or viral myocarditis patients, despite elevated white blood cell counts. In patients with acute heart failure, only miR-499 was significantly elevated (2-fold), whereas no significant changes in microRNAs studied could be observed in diastolic dysfunction. Remarkably, plasma microRNA levels were not affected by a wide range of clinical confounders, including age, sex, body mass index, kidney function, systolic blood pressure, and white blood cell count. CONCLUSIONS: Cardiac damage initiates the detectable release of cardiomyocyte-specific microRNAs-208b and -499 into the circulation.

BACKGROUND: Evidence for efficacy of dual antiplatelet therapy in stroke is limited. Symptomatic carotid stenosis patients are at high risk of early recurrent stroke. In this group, asymptomatic microembolic signals (MES), detected by transcranial Doppler ultrasound (TCD), are markers of future stroke and transient ischemic attack (TIA) risk. They offer a surrogate marker to evaluate antiplatelet therapy, but no multicenter study has evaluated the feasibility of this approach. METHODS AND RESULTS: Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) is a randomized, double-blind study in subjects with recently symptomatic > or =50% carotid stenosis. Patients were screened with TCD, and if MES were detected, they were randomized to clopidogrel and aspirin or aspirin monotherapy. Repeated TCD recordings were made on days 2 and 7. MES were detected in 110 of 230 patients by online analysis at baseline, of whom 107 were randomized. Intention-to-treat analysis revealed a significant reduction in the primary end point: 43.8% of dual-therapy patients were MES positive on day 7, as compared with 72.7% of monotherapy patients (relative risk reduction 39.8%; 95% CI, 13.8 to 58.0; P=0.0046). The secondary end point of MES frequency per hour was reduced (compared with baseline) by 61.4% (95% CI, 31.6 to 78.2; P=0.0013) in the dual-therapy group at day 7 and by 61.6% (95% CI, 34.9 to 77.4; P=0.0005) on day 2. There were 4 recurrent strokes and 7 TIAs in the monotherapy group versus no stroke and 4 TIAs in the dual-therapy group that were treatment emergent and ipsilateral to the qualifying carotid stenosis; 2 additional ipsilateral TIAs occurred before treatment started. MES frequency was greater in the 17 patients with recurrent ipsilateral events compared with the 90 without (mean+/-SD: 24.4+/-27.7 versus 8.9+/-11.5 per hour; P=0.0003). CONCLUSIONS: In patients with recently symptomatic carotid stenosis, combination therapy with clopidogrel and aspirin is more effective than aspirin alone in reducing asymptomatic embolization. Doppler MES detection is a feasible method to evaluate the efficacy of antiplatelet therapy in multicenter studies.

Mutations in SCN2A, a gene encoding the voltage-gated sodium channel Nav1.2, have been associated with a spectrum of epilepsies and neurodevelopmental disorders. Here, we report the phenotypes of 71 patients and review 130 previously reported patients. We found that (i) encephalopathies with infantile/childhood onset epilepsies (≥3 months of age) occur almost as often as those with an early infantile onset (<3 months), and are thus more frequent than previously reported; (ii) distinct phenotypes can be seen within the late onset group, including myoclonic-atonic epilepsy (two patients), Lennox-Gastaut not emerging from West syndrome (two patients), and focal epilepsies with an electrical status epilepticus during slow sleep-like EEG pattern (six patients); and (iii) West syndrome constitutes a common phenotype with a major recurring mutation (p.Arg853Gln: two new and four previously reported children). Other known phenotypes include Ohtahara syndrome, epilepsy of infancy with migrating focal seizures, and intellectual disability or autism without epilepsy. To assess the response to antiepileptic therapy, we retrospectively reviewed the treatment regimen and the course of the epilepsy in 66 patients for which well-documented medical information was available. We find that the use of sodium channel blockers was often associated with clinically relevant seizure reduction or seizure freedom in children with early infantile epilepsies (<3 months), whereas other antiepileptic drugs were less effective. In contrast, sodium channel blockers were rarely effective in epilepsies with later onset (≥3 months) and sometimes induced seizure worsening. Regarding the genetic findings, truncating mutations were exclusively seen in patients with late onset epilepsies and lack of response to sodium channel blockers. Functional characterization of four selected missense mutations using whole cell patch-clamping in tsA201 cells-together with data from the literature-suggest that mutations associated with early infantile epilepsy result in increased sodium channel activity with gain-of-function, characterized by slowing of fast inactivation, acceleration of its recovery or increased persistent sodium current. Further, a good response to sodium channel blockers clinically was found to be associated with a relatively small gain-of-function. In contrast, mutations in patients with late-onset forms and an insufficient response to sodium channel blockers were associated with loss-of-function effects, including a depolarizing shift of voltage-dependent activation or a hyperpolarizing shift of channel availability (steady-state inactivation). Our clinical and experimental data suggest a correlation between age at disease onset, response to sodium channel blockers and the functional properties of mutations in children with SCN2A-related epilepsy.

The gastrointestinal tract is abundantly colonized by microbes, yet the translocation of oral species to the intestine is considered a rare aberrant event, and a hallmark of disease. By studying salivary and fecal microbial strain populations of 310 species in 470 individuals from five countries, we found that transmission to, and subsequent colonization of, the large intestine by oral microbes is common and extensive among healthy individuals. We found evidence for a vast majority of oral species to be transferable, with increased levels of transmission in colorectal cancer and rheumatoid arthritis patients and, more generally, for species described as opportunistic pathogens. This establishes the oral cavity as an endogenous reservoir for gut microbial strains, and oral-fecal transmission as an important process that shapes the gastrointestinal microbiome in health and disease.

The identity and unique capacity of cancer stem cells (CSC) to drive tumor growth and resistance have been challenged in brain tumors. Here we report that cells expressing CSC-associated cell membrane markers in Glioblastoma (GBM) do not represent a clonal entity defined by distinct functional properties and transcriptomic profiles, but rather a plastic state that most cancer cells can adopt. We show that phenotypic heterogeneity arises from non-hierarchical, reversible state transitions, instructed by the microenvironment and is predictable by mathematical modeling. Although functional stem cell properties were similar in vitro, accelerated reconstitution of heterogeneity provides a growth advantage in vivo, suggesting that tumorigenic potential is linked to intrinsic plasticity rather than CSC multipotency. The capacity of any given cancer cell to reconstitute tumor heterogeneity cautions against therapies targeting CSC-associated membrane epitopes. Instead inherent cancer cell plasticity emerges as a novel relevant target for treatment.

Aerobic exercise intensity prescription is a key issue in cardiac rehabilitation, being directly linked to both the amount of improvement in exercise capacity and the risk of adverse events during exercise. This joint position statement aims to provide professionals with up-to-date information regarding the identification of different exercise intensity domains, the methods of direct and indirect determination of exercise intensity for both continuous and interval aerobic training, the effects of the use of different exercise protocols on exercise intensity prescription and the indications for recommended exercise training prescription in specific cardiac patients' groups. The importance of functional evaluation through exercise testing prior to starting an aerobic training program is strongly emphasized, and ramp incremental cardiopulmonary exercise test, when available, is proposed as the gold standard for a physiologically comprehensive exercise intensity assessment and prescription. This may allow a shift from a 'range-based' to a 'threshold-based' aerobic exercise intensity prescription, which, combined with thorough clinical evaluation and exercise-related risk assessment, could maximize the benefits obtainable by the use of aerobic exercise training in cardiac rehabilitation.

RATIONALE: Long noncoding RNAs (lncRNAs) constitute a novel class of noncoding RNAs that regulate gene expression. Although recent data suggest that lncRNAs may be associated with cardiac disease, little is known about lncRNAs in the setting of myocardial ischemia. OBJECTIVE: To measure lncRNAs in patients with myocardial infarction (MI). METHODS AND RESULTS: We enrolled 414 patients with acute MI treated by primary percutaneous coronary intervention. Blood samples were harvested at the time of reperfusion. Expression levels of 5 lncRNAs were measured in peripheral blood cells by quantitative polymerase chain reaction: hypoxia inducible factor 1A antisense RNA 2, cyclin-dependent kinase inhibitor 2B antisense RNA 1 (ANRIL), potassium voltage-gated channel, KQT-like subfamily, member 1 opposite strand/antisense transcript 1 (KCNQ1OT1), myocardial infarction-associated transcript, and metastasis-associated lung adenocarcinoma transcript 1. Levels of hypoxia inducible factor 1A antisense RNA 2, KCNQ1OT1, and metastasis-associated lung adenocarcinoma transcript 1 were higher in patients with MI than in healthy volunteers (P<0.01), and levels of ANRIL were lower in patients with MI (P=0.003). Patients with ST-segment-elevation MI had lower levels of ANRIL (P<0.001), KCNQ1OT1 (P<0.001), myocardial infarction-associated transcript (P<0.001), and metastasis-associated lung adenocarcinoma transcript 1 (P=0.005) when compared with patients with non-ST-segment-elevation MI. Levels of ANRIL were associated with age, diabetes mellitus, and hypertension. Patients presenting within 3 hours of chest pain onset had elevated levels of hypoxia inducible factor 1A antisense RNA 2 when compared with patients presenting later on. ANRIL, KCNQ1OT1, myocardial infarction-associated transcript, and metastasis-associated lung adenocarcinoma transcript 1 were significant univariable predictors of left ventricular dysfunction as assessed by an ejection fraction ≤40% at 4-month follow-up. In multivariable and reclassification analyses, ANRIL and KCNQ1OT1 improved the prediction of left ventricular dysfunction by a model, including demographic features, clinical parameters, and cardiac biomarkers. CONCLUSIONS: Levels of lncRNAs in blood cells are regulated after MI and may help in prediction of outcome. This motivates further investigation of the role of lncRNAs after MI.

AIMS/HYPOTHESIS: The aim of this multicentre, randomised, controlled crossover study was to determine the efficacy of adding continuous glucose monitoring (CGM) to insulin pump therapy (CSII) in type 1 diabetes. METHODS: Children and adults (n = 153) on CSII with HbA(1c) 7.5-9.5% (58.5-80.3 mmol/mol) were randomised to (CGM) a Sensor On or Sensor Off arm for 6 months. After 4 months' washout, participants crossed over to the other arm for 6 months. Paediatric and adult participants were separately electronically randomised through the case report form according to a predefined randomisation sequence in eight secondary and tertiary centres. The primary outcome was the difference in HbA(1c) levels between arms after 6 months. RESULTS: Seventy-seven participants were randomised to the On/Off sequence and 76 to the Off/On sequence; all were included in the primary analysis. The mean difference in HbA(1c) was -0.43% (-4.74 mmol/mol) in favour of the Sensor On arm (8.04% [64.34 mmol/mol] vs 8.47% [69.08 mmol/mol]; 95% CI -0.32%, -0.55% [-3.50, -6.01 mmol/mol]; p < 0.001). Following cessation of glucose sensing, HbA(1c) reverted to baseline levels. Less time was spent with sensor glucose <3.9 mmol/l during the Sensor On arm than in the Sensor Off arm (19 vs 31 min/day; p = 0.009). The mean number of daily boluses increased in the Sensor On arm (6.8 ± 2.5 vs 5.8 ± 1.9, p < 0.0001), together with the frequency of use of the temporary basal rate (0.75 ± 1.11 vs 0.26 ± 0.47, p < 0.0001) and manual insulin suspend (0.91 ± 1.25 vs 0.70 ± 0.75, p < 0.018) functions. Four vs two events of severe hypoglycaemia occurred in the Sensor On and Sensor Off arm, respectively (p = 0.40). CONCLUSIONS/INTERPRETATION: Continuous glucose monitoring was associated with decreased HbA(1c) levels and time spent in hypoglycaemia in individuals with type 1 diabetes using CSII. More frequent self-adjustments of insulin therapy may have contributed to these effects.

Exosomes derived from solid tumor cells are involved in immune suppression, angiogenesis, and metastasis, but the role of leukemia-derived exosomes has been less investigated. The pathogenesis of chronic lymphocytic leukemia (CLL) is stringently associated with a tumor-supportive microenvironment and a dysfunctional immune system. Here, we explore the role of CLL-derived exosomes in the cellular and molecular mechanisms by which malignant cells create this favorable surrounding. We show that CLL-derived exosomes are actively incorporated by endothelial and mesenchymal stem cells ex vivo and in vivo and that the transfer of exosomal protein and microRNA induces an inflammatory phenotype in the target cells, which resembles the phenotype of cancer-associated fibroblasts (CAFs). As a result, stromal cells show enhanced proliferation, migration, and secretion of inflammatory cytokines, contributing to a tumor-supportive microenvironment. Exosome uptake by endothelial cells increased angiogenesis ex vivo and in vivo, and coinjection of CLL-derived exosomes and CLL cells promoted tumor growth in immunodeficient mice. Finally, we detected α-smooth actin-positive stromal cells in lymph nodes of CLL patients. These findings demonstrate that CLL-derived exosomes actively promote disease progression by modulating several functions of surrounding stromal cells that acquire features of cancer-associated fibroblasts.

BACKGROUND: Therapeutic hypothermia (TH) after cardiac arrest protects from neurological sequels and death and is recommended in guidelines. The Hypothermia Registry was founded to the monitor outcome, performance and complications of TH. METHODS: Data on out-of-hospital cardiac arrest (OHCA) patients admitted to intensive care for TH were registered. Hospital survival and long-term outcome (6-12 months) were documented using the Cerebral Performance Category (CPC) scale, CPC 1-2 representing a good outcome and 3-5 a bad outcome. RESULTS: From October 2004 to October 2008, 986 TH-treated OHCA patients of all causes were included in the registry. Long-term outcome was reported in 975 patients. The median time from arrest to initiation of TH was 90 min (interquartile range, 60-165 min) and time to achieving the target temperature (< or =34 degrees C) was 260 min (178-400 min). Half of the patients underwent coronary angiography and one-third underwent percutaneous coronary intervention (PCI). Higher age, longer time to return of spontaneous circulation, lower Glasgow Coma Scale at admission, unwitnessed arrest and initial rhythm asystole were all predictors of bad outcome, whereas time to initiation of TH and time to reach the goal temperature had no significant association. Bleeding requiring transfusion occurred in 4% of patients, with a significantly higher risk if angiography/PCI was performed (2.8% vs. 6.2%P=0.02). CONCLUSIONS: Half of the patients survived, with >90% having a good neurological function at long-term follow-up. Factors related to the timing of TH had no apparent association to outcome. The incidence of adverse events was acceptable but the risk of bleeding was increased if angiography/PCI was performed.

Importance: Insulin pump therapy may improve metabolic control in young patients with type 1 diabetes, but the association with short-term diabetes complications is unclear. Objective: To determine whether rates of severe hypoglycemia and diabetic ketoacidosis are lower with insulin pump therapy compared with insulin injection therapy in children, adolescents, and young adults with type 1 diabetes. Design, Setting, and Participants: Population-based cohort study conducted between January 2011 and December 2015 in 446 diabetes centers participating in the Diabetes Prospective Follow-up Initiative in Germany, Austria, and Luxembourg. Patients with type 1 diabetes younger than 20 years and diabetes duration of more than 1 year were identified. Propensity score matching and inverse probability of treatment weighting analyses with age, sex, diabetes duration, migration background (defined as place of birth outside of Germany or Austria), body mass index, and glycated hemoglobin as covariates were used to account for relevant confounders. Exposures: Type 1 diabetes treated with insulin pump therapy or with multiple (≥4) daily insulin injections. Main Outcomes and Measures: Primary outcomes were rates of severe hypoglycemia and diabetic ketoacidosis during the most recent treatment year. Secondary outcomes included glycated hemoglobin levels, insulin dose, and body mass index. Results: Of 30 579 patients (mean age, 14.1 years [SD, 4.0]; 53% male), 14 119 used pump therapy (median duration, 3.7 years) and 16 460 used insulin injections (median duration, 3.6 years). Patients using pump therapy (n = 9814) were matched with 9814 patients using injection therapy. Pump therapy, compared with injection therapy, was associated with lower rates of severe hypoglycemia (9.55 vs 13.97 per 100 patient-years; difference, -4.42 [95% CI, -6.15 to -2.69]; P < .001) and diabetic ketoacidosis (3.64 vs 4.26 per 100 patient-years; difference, -0.63 [95% CI, -1.24 to -0.02]; P = .04). Glycated hemoglobin levels were lower with pump therapy than with injection therapy (8.04% vs 8.22%; difference, -0.18 [95% CI, -0.22 to -0.13], P < .001). Total daily insulin doses were lower for pump therapy compared with injection therapy (0.84 U/kg vs 0.98 U/kg; difference, -0.14 [-0.15 to -0.13], P < .001). There was no significant difference in body mass index between both treatment regimens. Similar results were obtained after propensity score inverse probability of treatment weighting analyses in the entire cohort. Conclusions and Relevance: Among young patients with type 1 diabetes, insulin pump therapy, compared with insulin injection therapy, was associated with lower risks of severe hypoglycemia and diabetic ketoacidosis and with better glycemic control during the most recent year of therapy. These findings provide evidence for improved clinical outcomes associated with insulin pump therapy compared with injection therapy in children, adolescents, and young adults with type 1 diabetes.

The significant and growing global prevalence of diabetes continues to challenge people with diabetes (PwD), healthcare providers, and payers. While maintaining near-normal glucose levels has been shown to prevent or delay the progression of the long-term complications of diabetes, a significant proportion of PwD are not attaining their glycemic goals. During the past 6 years, we have seen tremendous advances in automated insulin delivery (AID) technologies. Numerous randomized controlled trials and real-world studies have shown that the use of AID systems is safe and effective in helping PwD achieve their long-term glycemic goals while reducing hypoglycemia risk. Thus, AID systems have recently become an integral part of diabetes management. However, recommendations for using AID systems in clinical settings have been lacking. Such guided recommendations are critical for AID success and acceptance. All clinicians working with PwD need to become familiar with the available systems in order to eliminate disparities in diabetes quality of care. This report provides much-needed guidance for clinicians who are interested in utilizing AIDs and presents a comprehensive listing of the evidence payers should consider when determining eligibility criteria for AID insurance coverage.